Grants & Sponsorships
Click on the tabs below to learn more about each of the different grant programs with IONIS, qualifications and requirements for each, and deadlines for submissions.
Click on the tabs below to learn more about each of the different grant programs with IONIS, qualifications and requirements for each, and deadlines for submissions.
As a part of our commitment to discover, develop, and deliver medicines to the patients who depend on us, we believe in supporting investigator-initiated research (IIR) to advance medical and scientific knowledge in our research areas of interest.
We define IIR as unsolicited research conceived, initiated, and conducted independently of Ionis. An external investigator serves as the sponsor, and with their institution, is wholly responsible for the design, implementation, conduct of the research, data collection, data interpretation, publication, and all compliance, quality, and regulatory requirements.
IIR proposals are evaluated on scientific merit, alignment with our research areas of interest, and availability of resources. Submission of a proposal does not guarantee Ionis' support.
Cardiovascular/Metabolic
Please submit grant proposal applications through our online Ionis Research Grants portal by clicking here: Apply Now. If a proposal is of interest, a request for full protocol submission will be issued.
If you have any questions regarding the Ionis IIR Grant program, please email [email protected]
For Technical Support with the Ionis IIR Portal, please contact SteepRock Client Services via email at [email protected] or phone at +1 (718) 576-1406 (M-F 8am – 6pm US ET).
Ionis Pharmaceuticals is pleased to announce the Ionis Young Investigator Grant (YIG). This grant was recently created by the division of CardioRenal-Metabolism within Medical Affairs to recognize early career investigators who are performing high quality research in the field of severe hypertriglyceridemia. Ionis values developing clinicians and scientists who will influence the field and support new research for years to come.
The Ionis YIG is a grant aimed at providing research grants to fellows who are at eligible academic or non-profit institutions and submit innovative research proposals in the areas of translational, clinical, or applied research. The Ionis YIG encourages early stage scientific investigators of promise to apply, who are engaged in cutting-edge research on the topic of severe hypertriglyceridemia for the following categories:
The goals of the research application should focus on understanding the effects of chylomicron and/or triglyceride elevations on cardiovascular and metabolic disease. Specifically, the grant will support 2 fellows, residents, or junior faculty annually to promote quality research and support the development of future researchers and clinicians.
This grant is awarded by an independent review committee on a competitive basis for a maximum of two academic years with the first year guaranteed and the second-year contingent on approval of a progress submission demonstrating progress towards the pre-stated research objectives and ongoing research.
Deadlines and Important Dates Based on Grant Program Approval
The following must be submitted via email to [email protected] to apply:
OR, if investigator not yet identified,
For more information, please contact Ionis Medical Affairs at [email protected].
Ionis recognizes the importance of Independent Medical Education (IME) and is committed to supporting programs that enhance patient care. Ionis supports targeted high-quality accredited and non-accredited medical education programs to advance excellence in healthcare by improving disease awareness, clinical knowledge, and multidisciplinary management within our therapeutic areas of focus.
IME is defined as education that is evidence-based, fair-balanced, unbiased, and independent of industry influence. Therefore, all aspects related to IME including but not limited to the agenda, content, and faculty, must remain fully independent and be under the sole control of the activity organizers. Ionis will not provide any guidance to the IME provider. All accredited programs must follow the standards set forth in the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education.
Requests with multiple potential supporters are preferred. Due to the number of requests received not all submitted requests will be approved or approved at the amount requested. Ionis will consider funding requests in the following therapeutic areas of focus for medical educational programs in the United States:
Hereditary Angioedema:
Severe Hypertriglyceridemia including genetic conditions such as Familial Chylomicronemia Syndrome:
All IME grant request applications must be submitted through our online Ionis Medical Grants portal by clicking here: Apply Now. Please note that the Grant requests must be submitted at least 60 calendar days prior to the program/event start date.
The following elements will be required when submitting the online grant request application. The submitter will be able to save their work and continue at another time. In addition to the required fields on our application form, the submitter will have the opportunity to upload PDF documents of additional information which may be relevant or taken into consideration.
Please note that the recipient of the grant must be an appropriate organization such as a hospital, university, school of medicine, nursing, or pharmacy, a professional society or association, a medical education communication company, or other institution specializing in specific healthcare-related disciplines (e.g., public health, quality improvement). Ionis does not support IME grant requests from healthcare providers, including individual physicians, private practice groups, group purchasing organizations, managed care organizations, preferred provider organizations, or similar institutions.
If you have any questions regarding the Ionis IME Grant program, please email [email protected].
For Technical Support with the Ionis Grant Portal, please contact SteepRock Client Services via email at [email protected] or phone at +1 (718) 576-1406 (M-F 8am – 6pm US ET).
Global and United States IME grants requests for amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PM) will now be submitted to and reviewed by our global development and commercialization partner AstraZeneca. Please visit www.astrazenecagrants.com to review the application procedure and/or to submit.